Revenues were $2.79 billion for Q3, up from $1.96 billion in the third quarter last year and beating the consensus Wall Street estimate of $2.73 billion.
The third quarter continued Abbott's streak of offsetting base business declines with COVID-19 testing, with 38 percent growth in the diagnostics business.
For the three months ended June 30, the firm reported revenues of $5.4 million, down from $6.3 million in the year-ago quarter and missing the consensus Wall Street estimate of $5.9 million.